About: Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19
Creator	Feizollahzadeh, Sadegh Sedokani, Amin
source	Medline; PMC; WHO
abstract	In March 2020, the WHO declared the COVID-19 disease as a pandemic disease. There have been studies on the COVID-19 to find a certain treatment, but yet, there is no certain cure. In this article, we present a possible way to treat severe cases of COVID-19. Based on the previous studies, there are similarities between the spike antigens of SARS-CoV and SARS-CoV-2 viruses. It is expected that these similarities (structural and affinity to the receptor of ACE2) can lead to the same pathophysiological activity of the virus by the use of ACE2 and FcγRII (the antibody-dependent enhancement mechanism). Therefore, we propose a way of washing out (by plasmapheresis) the possible antibodies against the spike protein of the virus out of patients’ plasma to stop the antibody-dependent enhancement (ADE)-mediated infection of the immune system cells at the first phase of the treatment and simultaneous use of the anti-ACE2 with anti-FcγRII monoclonal antibodies at the second phase. We propose these procedures for the patients that have no significant response for typical anti-viral, ARDS and conservative therapies, and the disease persists or progresses despite sufficient therapies.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.2147/dddt.s262491
bibo:pmid	32753842
has license	cc-by-nc
sha1sum (hex)	1b8562271189fc30aa56ead2a083d8a2a4fbb8a6
schema:url	https://doi.org/10.2147/dddt.s262491
resource representing a document's title	Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19
has PubMed Central identifier	PMC7351975
has PubMed identifier	32753842
schema:publication	Drug Des Devel Ther
resource representing a document's body	covid:1b8562271189fc30aa56ead2a083d8a2a4fbb8a6#body_text
is schema:about of	named entity 'washing' named entity 'Cases' named entity 'Treatment' named entity 'THERAPIES' named entity 'ARDS' covid:arg/1b8562271189fc30aa56ead2a083d8a2a4fbb8a6 named entity 'affinity' named entity 'antigens' named entity 'virus' named entity 'spike' named entity 'therapies' named entity 'antibody-dependent enhancement' named entity 'spike' named entity 'pandemic disease' named entity 'ACE2' named entity 'virus' named entity 'pathophysiological' named entity 'ACE2' named entity 'antibody-dependent enhancement' named entity 'ARDS' named entity 'ACE2' named entity 'immune system cells' named entity 'spike protein' named entity 'viruses' named entity 'plasma' named entity 'infection' named entity 'studies' named entity 'SARS-CoV' named entity 'antibody-dependent enhancement' named entity 'BASED' named entity 'TO STOP' named entity 'WAY' named entity 'AFFINITY' named entity 'VIRAL' named entity 'THESE' named entity 'SARS-COV-2' named entity 'ADE' named entity 'anti-viral' named entity 'March 2020' named entity 'virus' named entity 'RECEPTOR' named entity 'PROGRESSES' named entity 'IMMUNE SYSTEM' named entity 'DISEASE' named entity 'PRESENT' named entity 'PLASMA' named entity 'WASHING OUT' named entity 'MONOCLONAL ANTIBODIES' named entity 'STUDIES' named entity 'SUFFICIENT' named entity 'CELLS' named entity 'VIRUSES' named entity 'LEAD' named entity 'ANTIGENS' named entity 'PATIENTS' named entity 'USE OF' named entity 'CASES' named entity 'WHO' named entity 'COVID-19' named entity 'SPIKE' named entity 'SIMULTANEOUS' named entity 'PROTEIN ' named entity 'POSSIBLE' named entity 'TYPICAL' named entity 'VIRUS' named entity 'TREAT' named entity 'SARS-COV' named entity 'CURE' named entity 'MARCH' named entity 'BUT' named entity 'PREVIOUS' named entity 'TREATMENT' named entity 'antigens' named entity 'monoclonal antibodies' named entity 'COVID' named entity 'plasmapheresis' named entity 'Plasmapheresis' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software